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OBJECTIVES: ERCP is the gold standard for pancreaticobili-
ary evaluation but is associated with complications. Less
invasive diagnostic alternatives with similar capabilities
may be cost-effective, particularly in situations involving
low prevalence of disease. The aim of this study was to
compare the performance of endoscopic ultrasound (EUS)
with magnetic resonance cholangiopancreatography
(MRCP) and ERCP in the same patients with suspected
extrahepatic biliary disease. The economic outcomes of
EUS-, MRCP-, and ERCP-based diagnostic strategies were
evaluated.
METHODS: Prospective cohort study of patients referred for
ERCP with suspected biliary disease. MRCP and EUS were
performed within 24 h before ERCP. The investigators were
blinded to the results of the alternative imaging studies. A
cost-utility analysis was performed for initial ERCP,
MRCP, and EUS strategies for these patients.
RESULTS: A total of 30 patients were studied. ERCP chol-
angiogram failed in one patient, and another patient did not
complete MRCP because of claustrophobia. The final diag-
noses (N  28) were CBD stone (mean  4 mm; range 
3–6 mm) in five patients; biliary stricture in three patients,
and normal biliary tree in 20. Two patients had pancreatitis
after therapeutic ERCP, one after precut sphincterotomy
followed by a normal cholangiogram. EUS was more sen-
sitive than MRCP in the detection of choledocolithiasis
(80% vs 40%), with similar specificity. MRCP had a poor
specificity and positive predictive value for the diagnosis of
biliary stricture (76%/25%) compared to EUS (100%/
100%), with similar sensitivity. The overall accuracy of
MRCP for any abnormality was 61% (95% CI  0.41–0.78)
compared to 89% (CI  0.72–0.98) for EUS. Among those
patients with a normal biliary tree, the proportion correctly
identified with each test was 95% for EUS and 65% for
MRCP (p  0.02). The cost for each strategy per patient
evaluated was $1346 for ERCP, $1111 for EUS, and $1145
for MRCP.
CONCLUSIONS: In this patient population with a low disease
prevalence, EUS was superior to MRCP for choledocholi-
thiasis. EUS was most useful for confirming a normal biliary
tree and should be considered a low-risk alternative to
ERCP. Although MRCP had the lowest procedural reim-
bursement, the initial EUS strategy had the greatest cost-
utility by avoiding unnecessary ERCP examinations. (Am J
Gastroenterol 2001;96:2900–2904. © 2001 by Am. Coll. of
Gastroenterology)
INTRODUCTION
Endoscopic retrograde cholangiopancreatography (ERCP)
remains the gold standard for evaluation of the pancreati-
cobiliary tree. The major drawback of this invasive proce-
dure is the potential for serious complications. The most
common serious and potentially life-threatening complica-
tions of ERCP are pancreatitis and cholangitis, which occur
respectively in 5.4% and 1.0% of patients undergoing biliary
sphincterotomy, even in expert centers (1). Although pancre-
atitis risk is increased with therapeutic ERCP, it may also occur
in the setting of diagnostic procedures. Although the therapeu-
tic potential of ERCP is unsurpassed by alternative imaging
procedures, less invasive diagnostic alternatives with similar
capabilities, such as endoscopic ultrasound (EUS) and mag-
netic resonance cholangiopancreatography (MRCP), can be
considered potential alternative imaging techniques.
Endoscopic ultrasound provides high quality images of
the pancreas and biliary tree. Prospective studies have sup-
ported the accuracy of EUS compared to ERCP in the
diagnosis of pancreatic and biliary conditions; in fact, in
highly experienced hands, EUS has been found to be more
sensitive than ERCP for choledocholithiasis (2). The prin-
cipal limitations of EUS are that it is an invasive procedure,
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its results are highly operator dependent, and procedure is
not widely available in clinical practice. In addition, pathol-
ogy identified at the time of EUS may require a subsequent
therapeutic ERCP. Despite these limitations, decision anal-
ysis has supported initial EUS as opposed to ERCP as a
screening tool in patients who have a low likelihood of
choledocholithiasis before laparoscopic cholecystectomy
(3). Even with both clinical and economic support for this
strategy, this approach is not commonly used in current
practice, given the practical considerations noted above.
Magnetic resonance cholangiopancreatography has
emerged as a potential noninvasive alternative approach to
evaluate the pancreaticobiliary system (4). Although the
equipment is costly and is still under development, the lack
of need for routine sedation, intravenous contrast, radiation
exposure, and greater availability than EUS render MRCP
an important alternative to diagnostic ERCP. Claustropho-
bia remains the major barrier to completion of the study.
MRCP has been compared to ERCP with impressive results
for tumor imaging (5); more variable results are seen in the
setting of benign strictures and stones (4, 6). These variable
results suggest that, as with EUS, the accuracy of MRCP is
dependent on experience in image interpretation as well as
on MR imaging techniques.
Although EUS and MRCP have compared favorably to
diagnostic ERCP in detecting extrahepatic biliary disease,
no study has directly compared the accuracy and clinical
utility of all three modalities in the same patients. We
hypothesized that these techniques may represent a viable
alternative to ERCP if they can demonstrate similar accu-
racy and fewer complications. Thus, we prospectively eval-
uated EUS and MRCP in patients referred for ERCP, ana-
lyzing the performance characteristics of each test and the




Consecutive adult patients (18 yr) who were referred and
scheduled for ERCP on the basis of clinical signs (abnormal
liver enzymes, abnormal transcutaneous ultrasound) and
symptoms (biliary pain) of biliary disease were recruited.
Patients with cholangitis, hypotension, or previously docu-
mented claustrophobia were excluded. For patients to be
eligible for the study, EUS and MRCP had to be performed
within 24 h before the ERCP. The University of Michigan
Institutional Review Board for Human Studies approved the
protocol, and patients provided written informed consent.
EUS Examination Technique
The Olympus (Tokyo, Japan) EUM-20 echoendoscope was
used. After conscious sedation, the echoendoscope was
placed in the duodenum and the extrahepatic biliary tract
was scanned from the duodenum upon instrument with-
drawal. The biliary tree was scanned from the papilla with
demonstration of a “stack sign”(where bile duct and pan-
creatic duct are visualized parallel to each other in the
pancreatic head) proximally to the hepatic hilum, if possible
(7). An experienced staff endosonographer performed and
interpreted the study with a trainee. This endosonographer
was blinded to the results of the MRCP and ERCP.
MRCP Technique
A 1.5-T magnet was used for all imaging (Signa, GE Med-
ical Systems, Milwaukee, WI). The body coil was used for
signal transmission and reception. Three pulse sequences
comprised the examination. An axial T-weighted localizer
was acquired. A fast spin echo, T2-weighted sequence in the
axial plane provided an overview of the upper abdomen.
The MRCP sequences were comprised of multiple contig-
uous images centered over the central biliary tree and ob-
tained in coronal and oblique planes. The sequence is a
single-shot, fast spin echo sequence that allowed an acqui-
sition time of 2 s/image, a total of 15 images/plane. Se-
quence parameters were as follows: effective T 185, band-
width 31.2 kHz, field of view 40 cm, slice thickness 5.0 mm,
0 spacing, interleaved acquisition, matrix 256  256, num-
ber of excitations 0.50, fat saturation pulse on. Images were
reviewed on a computer workstation (Advantage Windows,
GE Medical Systems) using multiple operator-defined ref-
ormations and maximum intensity projection (MIP) images.
The MRCP was analyzed by an experienced radiologist who
was blinded to the results of the EUS and ERCP.
ERCP Technique
The ERCP was performed using a standard Pentax (Orange-
burg, NY) duodenoscope by an experienced staff biliary
endoscopist assisted by a trainee. The operators were
blinded to the results of the EUS and MRCP when the
images were interpreted.
Interpretation of Imaging Tests
The common bile duct (CBD) was interpreted as dilated if
it measured 6 mm in patients with intact gallbladders (8
mm if the patient was postcholecystectomy) by EUS and
MRCP, or 10 mm by ERCP (12 mm postcholecystec-
tomy). The presence, size, and number of stones were re-
corded. Strictures, masses, and their locations were identi-
fied. All endoscopists and radiologists participating in the
study recorded their findings independently on a standard-
ized data form.
Data Analysis
Descriptive statistics were used to analyze the performance
characteristics of each diagnostic procedure. Confidence
intervals were calculated for the overall accuracy of EUS
and MRCP. To compare the proportion of patients without
disease correctly identified, the 2 test with Yates correction
was employed. Data were analyzed on a per-protocol basis.
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Cost Analysis
An analysis of total costs per patient diagnosed was per-
formed. This analysis used actual Medicare procedural re-
imbursement rates for the year 2000 as a measure of cost.
We included initial “less invasive” procedure costs and
subsequent ERCP costs only if they would have been re-
quired based on the final diagnosis. Disease management
costs included those associated with true positive, false-
positive, and false-negative results. For the ERCP group, the
cost per patient included all observed episodes of post-
ERCP pancreatitis. No bleeding occurred in this group.
For the initial EUS and MRCP strategies, we assumed
ERCP was associated with a pancreatitis rate of 5.4% (1).
Because no bleeding occurred in our ERCP cases, we did
not include an ERCP associated bleeding risk. EUS was
assumed to have a rate of bleeding of 0.1%. Modeling the
outcomes of patients with missed stones and strictures is
more problematic. We assumed that, in addition to the
need for eventual ERCP, 80% of patients developed
symptoms requiring an emergency department visit with
transcutaneous ultrasound, and 10% developed biliary
colic/cholangitis requiring admission. The cost per pro-
cedure and hospitalization (Diagnosis-Related Group
[DRG]) was taken from 2000 Medicare reimbursement
data and is shown in Table 1.
RESULTS
During the study, 30 patients were recruited. There was one
failed ERCP cholangiogram and one failed MRCP related to
claustrophobia. Complete data were available for 28 patients
(14 male, 14 female); these data comprise the per-proto-
col evaluation. The mean age of the patients studied was
46.5 yr, with a range of 23– 68 yr. There were five
patients with choledocholithiasis, three with biliary stric-
tures, and 20 with a normal biliary tree. In the patients
with strictures, two were secondary to a pancreatic mass
and one was caused by primary sclerosing cholangitis.
Two patients experienced post-ERCP pancreatitis. One of
these patients had a precut sphincterotomy performed
because of a strong suspicion of stones. The subsequent
cholangiogram found no stones. This outcome points out
both the clinical and economic importance of a treatment
strategy that limits use of the highest-risk test only to
those patients with disease.
The performance characteristics of EUS and MRCP for
the detection of choledocholithiasis are summarized in Ta-
ble 2. EUS was superior to MRCP in detecting CBD stones
and approached the sensitivity of ERCP. EUS had one
false-positive and one false-negative study, whereas MRCP
had three false-negative studies and one false-positive. All
of the patients had small stones (mean  4 mm, range 
3–6 mm).
The performance characteristics of MRCP and EUS in the
diagnosis of biliary strictures are summarized in Table 3.
ERCP was superior to both EUS and MRCP in detecting
biliary strictures. EUS was associated with one false-nega-
tive study (in the patient with PSC), and MRCP with one
false-negative study and six false-positives. The overall
accuracy of MRCP for any abnormality was 61% (95%
CI  0.41–0.78) compared to 89% (CI  0.72–0.98) for
EUS.
Because the specificity of EUS and MRCP are most
critical in defining those patients without disease, who do
not need ERCP, we compared the proportion correctly iden-
tified as free of disease with each test and found that the
difference was significant (p  0.02 by 2 test) (Fig. 1).
In evaluating the cost-utility of the initial EUS and MRCP
based strategies compared with initial ERCP, EUS was
associated with the lowest disease management cost (Ta-
ble 4). Despite the low reimbursement for MRCP com-
pared to EUS, in our population the use of EUS for the
initial study was associated with the lowest overall cost
per patient evaluated, followed by MRCP and then by
ERCP. This was related to the downstream costs associ-
ated with the failure to detect stones and the incorrect
identification of strictures, which prompted additional,
otherwise avoidable ERCPs.
DISCUSSION
In our cohort, when compared with initial ERCP or MRCP,
EUS was the most cost-effective initial imaging modality
for patients with extrahepatic disease. Our study, by its







ERCP (diagnostic) 428 511 939
ERCP (therapeutic) 511 511 1058
EUS 333 347 680
MRCP* 407
Emergency room visit* 175







* Total charge not separated into professional and facility components.
Table 2. Performance of EUS and MRCP for Detection of
Choledocholithiasis (n  5)
Sensitivity Specificity PPV NPV
EUS 80 95 80 96
MRCP 40 96 66 88
Table 3. Performance of EUS and MRCP for Evaluation of
Biliary Strictures (n  3)
Sensitivity Specificity PPV NPV
EUS 67 100 100 96
MRCP 67 76 25 95
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ambitious design requiring both less invasive tests to be
completed within 24 h, excluded (from a practical stand-
point) patients with the need for urgent ERCP, biasing the
study to include many patients with a normal biliary tree.
Our observation regarding the clinically important differ-
ence in overall accuracy of the two tests (61% vs 89%) can
therefore be generalized only to populations with a low
disease prevalence. Despite the overlap in 95% CI, support-
ing the need for a larger study to confirm these findings, the
differences in specificity among the patients without disease
had both clinical and economic impacts. By performing a
simultaneous comparison of both MRCP and EUS, our
unusual design does provide information previously un-
available in the literature. However, because of the rela-
tively small number of patients studied and the low preva-
lence of disease, the study cannot provide broad conclusions
regarding the overall diagnostic performance of EUS and
MRCP.
With regard to EUS, our study supports previous data
demonstrating a very high sensitivity and specificity for
choledocholithiasis. In a recent decision analysis by Sahai et
al. (3), a comprehensive review of the literature summariz-
ing prospective studies of EUS for the detection of bile duct
stones led to weighted averages of a sensitivity of 92% and
a specificity of 98%. Our data are consistent with prior
literature, with our reduced sensitivity reflecting a single
missed stone (one in five) in a population with a low
prevalence of disease. These investigators concluded that if
expert EUS was available, only high-risk patients (55%
likelihood of stones) should have ERCP as the initial test.
Given our low disease prevalence, the cost-analysis of our
prospective cohort study provides real-world outcome data
to support the results of the previously mentioned economic
model. The fact that a patient with suspected biliary stone
disease developed a sphincterotomy complication after fail-
ure of traditional cannulation techniques only emphasizes
the potential clinical and economic value of EUS before
ERCP in low-risk patients, given its high specificity in
patients with a normal biliary tree.
We found that EUS and MRCP provided adjunctive in-
formation for the two patients with biliary obstruction re-
lated to masses, but were poor for delineating benign biliary
strictures such as those arising from primary sclerosing
cholangitis. The value of EUS in detecting and staging small
pancreatic tumors is unquestioned; however, ERCP retains
value in its diagnostic and, most importantly, its therapeutic
potential both to sample the stricture by cytology and to
relieve obstruction with stenting techniques (8). In our study
patients, the cause of the obstruction was not determined by
traditional imaging tests such as transcutaneous ultrasound
or computed tomographic scanning. Thus, the referring phy-
sician requested ERCP for primarily diagnostic purposes.
Our results suggest that use of EUS or MRCP is reasonable
as the initial test in this situation, and supports ERCP as the
initial test when a stricture is likely, given the therapeutic
and diagnostic benefits of this technique.
In our study, a major deficiency of MRCP was in the
diagnosis of small biliary stones. As our patients were
symptomatic, the value of diagnosis and treatment seems
clear, however, there is controversy in the literature regard-
ing the natural history of asymptomatic small stones (9),
such as those found at the time of laparoscopic cholecys-
tectomy. Although prospective outcome data would be re-
quired, in our study MRCP missed stones in three of five
patients, and our economic analysis assumed, at 1 yr, that
the majority (90%) would have symptoms, with 10% re-
quiring hospitalization. Because the patients in this study
were referred for ERCP, they are not representative of the
asymptomatic stone population and are likely to be at
greater risk for both cholangitis and pancreatitis. The failure
of MRCP to detect small stones has also been confirmed by
other investigators (6).
We found that MRCP was not specific in the diagnosis of
biliary strictures. This problem may lead to further diagnos-
tic testing in patients with a normal biliary tree. The signif-
icant downstream clinical and economic costs, as reflected
in our cost analysis, negated the lower cost associated with
the procedure. This would further support the superiority of
EUS in this clinical situation (100% specificity) on both
clinical and economic grounds, despite its invasive nature.
MRCP also could not be completed in one patient because
of claustrophobia. An “intent to treat” analysis, although not
appropriate for this study, would worsen the performance
Figure 1. Specificity of EUS and MRCP for identifying a normal
biliary tree. Among those patients without biliary pathology, a
significantly greater proportion of cases were correctly identified
with EUS compared to MRCP.
Table 4. Cost-Utility Analysis
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characteristics of the MRCP if this patient were considered
an imaging failure.
The MRCP results in the literature are quite variable, and
our results are well within the range of previous reports (6,
10–13). Such variability likely reflects differences in both
equipment and expertise. These factors may have played a
role in this study performed in 1998–1999. Although the
endosonographers had a minimum of 4 yr experience, the
radiologists had less experience with MRCP, despite their
considerable MR body imaging experience. The more recent
MR literature suggests innovations in technology may also
lead to better diagnostic accuracy, as seen in recent studies
largely outside of the United States (11, 12). Using the
performance characteristics for EUS and MRCP in this
study, our cost analysis determined that EUS was the pre-
ferred initial diagnostic test, yielding an average cost of
$1111 per patient evaluated. However, the average cost per
patient for MRCP—a noninvasive test—was $1145. Given
the small cost difference, modest improvements in MRCP
sensitivity and specificity may result in MRCP as the pre-
ferred initial test in the evaluation of individuals with sus-
pected biliary disease. Furthermore, although Medicare re-
imbursement is typically used as an estimate for such cost
comparisons, the true cost of procedures may differ sub-
stantially from Medicare reimbursement. This is a relevant
consideration when applying our results to other health care
systems. Because actual clinical practice varies to the same
degree as the literature, the current cost analysis provides a
framework for performing similar economic analyses for
each practice. Prospective studies such as this one, although
challenging to perform, will likely be needed as MRCP
technology improves.
The failure of efforts to reduce ERCP pancreatitis man-
dates the development of less invasive alternatives such as
EUS and MRCP, particularly in populations with low prev-
alence of disease (14). The development of new EUS tech-
nologies such as the transverse linear array technology holds
the potential to develop a single endoscope that can provide
biliary images and allow the operator to proceed with ERCP
if necessary. With such an instrument in expert hands, we
predict that the benefits to the patient and health care system
will be substantial.
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